MGX
Metagenomi Therapeutics, Inc.Company Information
- Company Name
- Metagenomi Therapeutics, Inc.
- CIK
- CIK0001785279
- Category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- Ticker: Exchange
- MGX: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2836
- SIC Description
- Biological Products, (No Diagnostic Substances)
- Ticker
- MGX
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-09-09
- Last sale
- 2026-09-08
- Shares purchased (TTM)
- 20,000
- Shares sold (TTM)
- 22,465
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 6,262,702
- Shares outstanding
- 37,658,250
- Ownership
- 16.63%
Earnings Market Reaction
- Filing date
- 2026-08-10
- Price on filing date
- —
- 1-month reaction
- -4.88%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 39 | 25 | 42 | 33 | 27 | 29 | 27 | 25 | 61 | 103 | ||||||
| Available For Sale Securities Debt Securities Current | 82 | 115 | 119 | 151 | 178 | 197 | 221 | 249 | 239 | 225 | ||||||
| Accounts Receivable Net Current | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | ||||||
| Prepaid Expense And Other Assets Current | 4 | 4 | 4 | 5 | 6 | 6 | 8 | 7 | 6 | 6 | ||||||
| Assets Current | 124 | 145 | 166 | 190 | 212 | 233 | 258 | 282 | 308 | 336 | ||||||
| Property Plant And Equipment Net | 10 | 11 | 12 | 14 | 15 | 17 | 18 | 20 | 21 | 21 | ||||||
| Long Term Investments | 2 | 2 | 2 | 2 | 2 | 3 | 3 | 11 | 11 | 11 | ||||||
| Operating Lease Right Of Use Asset | 32 | 34 | 35 | 36 | 37 | 39 | 40 | 40 | 41 | 42 | ||||||
| Other Assets Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | ||||||
| Restricted Cash Noncurrent | 4 | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | ||||||
| Assets | 174 | 197 | 221 | 248 | 272 | 298 | 325 | 358 | 386 | 415 | ||||||
Liabilities Current | ||||||||||||||||
| Accounts Payable Current | 3 | 2 | 1 | 1 | 3 | 3 | 1 | 3 | 3 | 7 | ||||||
| Accrued Liabilities And Other Liabilities | 8 | 5 | 7 | 10 | 6 | 6 | 8 | 9 | 11 | 7 | ||||||
| Accrued Income Taxes Current | - | - | - | - | - | - | 0 | 0 | 0 | 3 | ||||||
| Operating Lease Liability Current | 6 | 6 | 6 | 6 | 6 | 6 | 6 | 5 | 5 | 4 | ||||||
| Contract With Customer Liability Current | 11 | 9 | 9 | 13 | 19 | 26 | 23 | 29 | 33 | 48 | ||||||
| Liabilities Current | 28 | 22 | 23 | 30 | 33 | 40 | 37 | 46 | 53 | 71 | ||||||
| Operating Lease Liability Noncurrent | 31 | 33 | 35 | 36 | 37 | 39 | 40 | 41 | 43 | 44 | ||||||
| Contract With Customer Liability Noncurrent | 0 | 2 | 3 | 2 | 4 | 4 | 10 | 12 | 17 | 20 | ||||||
| Other Liabilities Noncurrent | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 3 | 4 | 5 | ||||||
| Liabilities | 61 | 59 | 63 | 69 | 76 | 85 | 90 | 103 | 116 | 140 | ||||||
Stockholders Equity | ||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Commitments And Contingencies | - | - | - | - | - | - | 0 | - | - | - | ||||||
| Temporary Equity Carrying Amount Attributable To Parent | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 474 | 472 | 469 | 466 | 463 | 460 | 457 | 454 | 451 | 446 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | 0 | 0 | 1 | 1 | 2 | -0 | -0 | ||||||
| Retained Earnings Accumulated Deficit | -361 | -334 | -311 | -288 | -268 | -248 | -223 | -200 | -181 | -170 | ||||||
| Stockholders Equity | 113 | 138 | 159 | 178 | 196 | 213 | 235 | 256 | 269 | 276 | ||||||
| Liabilities And Stockholders Equity | 174 | 197 | 221 | 248 | 272 | 298 | 325 | 358 | 386 | 415 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Temporary Equity Shares Authorized | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Temporary Equity Shares Issued | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Temporary Equity Shares Outstanding | - | - | - | - | - | - | 0 | 0 | 0 | 0 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | ||||||
| Common Stock Shares Issued | 38 | 38 | 38 | 38 | 38 | 37 | 37 | 37 | 37 | 37 | ||||||
| Shares Outstanding | 38 | 38 | 38 | 38 | 38 | 37 | 37 | 37 | 37 | 37 | ||||||
Select a line item above to chart it.
Recent filings
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialMetagenomi Therapeutics, Inc. (MGX) — SEC Financial Statements & Analysis
Metagenomi Therapeutics, Inc. (MGX) is a biological products, (no diagnostic substances) company. Metagenomi Therapeutics, Inc. trades on Nasdaq as: MGX. Metagenomi Therapeutics, Inc. (MGX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10. Based on that filing, Metagenomi Therapeutics, Inc. carries a market cap of $44.81M, a P/E ratio of -0.48x, a P/B ratio of 0.40x, a P/S ratio of 3.24x, an enterprise value of $1.39M, and an EV/EBITDA multiple of -0.01x. On profitability, it posts an operating margin of -727.79%, a net margin of -676.38%, a Return on Equity (ROE) of -60.61%, a Return on Assets (ROA) of -41.91%, and a Return on Invested Capital (ROIC) of -86.02%. Per share, it reports EPS of $-2.48, diluted EPS of $-2.48, free cash flow per share of $-2.28, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -59.08% year-over-year, net income growth of 7.28% year-over-year, and EPS growth of 5.85% year-over-year. On the balance sheet, it maintains a current ratio of 4.50x, a quick ratio of 4.37x, working capital of $96.84M, a debt-to-equity ratio of 0.54x, a debt ratio of 0.35, free cash flow of $-85.80M (TTM), and net debt of $-43.42M. Figures sourced from SEC EDGAR.
- Market Cap
- $44.81M
- P/E TTM
- -0.48x
- EPS TTM
- $-2.48
- P/B TTM
- 0.40x
- ROE TTM
- -60.61%
- ROA TTM
- -41.91%
- Debt To Equity
- 0.54x
- Free Cash Flow TTM
- $-85.80M
- Net Revenue TTM Growth 1Y
- -59.08%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Metagenomi Therapeutics, Inc. in?
Metagenomi Therapeutics, Inc. (MGX) operates in the Biological Products, (No Diagnostic Substances) industry.
What exchange does MGX trade on?
Metagenomi Therapeutics, Inc. (MGX) trades on the Nasdaq.
When was Metagenomi Therapeutics, Inc. (MGX)'s most recent SEC filing?
Metagenomi Therapeutics, Inc. (MGX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-10.
What is MGX's market cap?
Metagenomi Therapeutics, Inc. (MGX) has a market capitalization of $44.81M as of 2026-06-30.
What is MGX's EPS (earnings per share)?
Metagenomi Therapeutics, Inc. (MGX)'s trailing twelve month EPS is $-2.48 as of 2026-06-30.
What is MGX's ROE (return on equity)?
Metagenomi Therapeutics, Inc. (MGX)'s trailing twelve month Return on Equity (ROE) is -60.61% as of 2026-06-30.
What is MGX's ROA (return on assets)?
Metagenomi Therapeutics, Inc. (MGX)'s trailing twelve month Return on Assets (ROA) is -41.91% as of 2026-06-30.
What is MGX's ROIC (return on invested capital)?
Metagenomi Therapeutics, Inc. (MGX)'s trailing twelve month Return on Invested Capital (ROIC) is -86.02% as of 2026-06-30.
What is MGX's EV/EBITDA?
Metagenomi Therapeutics, Inc. (MGX)'s trailing twelve month EV/EBITDA is -0.01x as of 2026-06-30.